These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8494577)

  • 1. Safety and tolerance of trospium chloride in the high dose range.
    Breuel HP; Mürtz G; Bondy S; Horkulak J; Gianetti BM
    Arzneimittelforschung; 1993 Apr; 43(4):461-4. PubMed ID: 8494577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
    Staskin D; Sand P; Zinner N; Dmochowski R;
    J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.
    Halaska M; Ralph G; Wiedemann A; Primus G; Ballering-Brühl B; Höfner K; Jonas U
    World J Urol; 2003 May; 20(6):392-9. PubMed ID: 12811500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
    MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
    Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily.
    Fröhlich G; Bulitta M; Strösser W
    Int J Clin Pharmacol Ther; 2002 Jul; 40(7):295-303. PubMed ID: 12139206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pupillometry: a non-invasive pharmacokinetic and pharmacodynamic method to study the action of trospium chloride (Spasmo-lyt) on smooth muscle].
    Albrecht H; Bruhn R; Lorenz D; Lücker PW; Schumacher M
    Methods Find Exp Clin Pharmacol; 1983 Oct; 5(8):585-7. PubMed ID: 6664161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase III trial studying trospium chloride in patients with overactive bladder.
    Rudy D; Cline K; Harris R; Goldberg K; Dmochowski R
    Urology; 2006 Feb; 67(2):275-80. PubMed ID: 16461077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test].
    Fröhlich G; Burmeister S; Wiedemann A; Bulitta M
    Arzneimittelforschung; 1998 May; 48(5):486-91. PubMed ID: 9638316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
    Ginsberg DA; Oefelein MG; Ellsworth PI
    Neurourol Urodyn; 2011 Apr; 30(4):563-7. PubMed ID: 21268101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
    Staskin DR; Cardozo L
    Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults.
    Silver N; Sandage B; Sabounjian L; Schwiderski U; Shipley J; Harnett M
    J Clin Pharmacol; 2010 Feb; 50(2):143-50. PubMed ID: 19948948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo.
    Kopera H
    Br J Clin Pharmacol; 1978; 5 Suppl 1(Suppl 1):29S-34S. PubMed ID: 341941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
    Dmochowski RR; Sand PK; Zinner NR; Staskin DR
    Urology; 2008 Mar; 71(3):449-54. PubMed ID: 18342185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High-dose trospium chloride in therapy of detrusor hyperreflexia].
    Madersbacher H; Stöhrer M; Richter R; Giannetti BM; Mürtz G
    Urologe A; 1991 Jul; 30(4):260-3. PubMed ID: 1926674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound studies of the effect of trospium chloride on gall-bladder kinetics.
    Matzkies F; Mürtz G; Giannetti B; Lenhard G; Schicketanz KH
    Arzneimittelforschung; 1992 Dec; 42(12):1456-8. PubMed ID: 1288510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with application of trospium chloride in patients with neurogenic detrusor overactivity].
    Shvarts PG; Kadykov AS; Shvedkov VV; Timerbaeva SL; Polevaia EV; Mulach AN
    Urologiia; 2009; (5):24-9. PubMed ID: 20213911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release.
    Chancellor MB; Oefelein MG; Vasavada S
    Neurourol Urodyn; 2010 Apr; 29(4):551-4. PubMed ID: 19634167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.